Clinical Trial

A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

Study acronym: VAYHIT-P
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to \<18 years of age) with primary ITP who have had an insufficient response to or relapsed after first-line treatment with corticosteroids.
Trial Details
NCT Number NCT07660172
Lead Sponsor Novartis Pharmaceuticals
Conditions Primary Immune Thrombocytopenia (ITP)
Enrollment 36 participants
Start Date 2027-02-08
Primary Completion 2033-04-22 (estimated)
Study Completion 2033-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-25